^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

onvapegleukin alfa (TransCon IL-2 β/γ)

i
Other names: TransCon IL-2 β/γ, TransCon Interleukin 2 beta/gamma, TransCon IL-2 b/g
Associations
Company:
Ascendis
Drug class:
CD122 agonist, IL-2R agonist, IL-2Rγ agonist
Associations
1m
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • Kadcyla (ado-trastuzumab emtansine) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)
11ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)
over1year
Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy (ESMO 2023)
The RP2D for monotherapy was determined at 120 mcg/kg IV every 3 weeks while dose escalation continues for combination therapy. PK data indicated a half-life of at least 35 hours and PD data confirm durable activation and expansion of cytotoxic immune cells from TransCon IL-2 β/γ.
P1/2 data • P2 data • Combination therapy
|
MSI (Microsatellite instability) • IL2 (Interleukin 2)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • onvapegleukin alfa (TransCon IL-2 β/γ)
over2years
IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumors. (ASCO 2022)
Recombinant human interleukin-2 (IL-2, aldesleukin) can induce a response rate of ̃15% in metastatic renal cell carcinoma and metastatic melanoma, yet toxicities (vascular leak syndrome, cytokine storm) have limited its use...Parts 1 and 2 Dose Escalation (Phase 1) use a standard 3+3 design with increasing doses of intravenous (IV) TransCon IL-2 b/g alone (Part 1) or with 200 mg IV pembrolizumab in solid tumors where pembrolizumab monotherapy may have clinical activity (Part 2)...Other key objectives include the evaluation of pharmacokinetics, pharmacodynamic biomarkers, and antitumor activity according to RECIST 1.1. Recruitment started in January 2022 and is ongoing (NCT05081609).
Clinical • P1/2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • IL2 (Interleukin 2)
|
PD-1 expression
|
Keytruda (pembrolizumab) • Proleukin (aldesleukin) • onvapegleukin alfa (TransCon IL-2 β/γ)
almost3years
Enrollment open • Combination therapy
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • onvapegleukin alfa (TransCon IL-2 β/γ)
3years
Clinical • New P1/2 trial • Combination therapy
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • onvapegleukin alfa (TransCon IL-2 β/γ)